Jean-Louis Pujol

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · Journal of Clinical Oncology · 2013 · 635 citations

Medicine, Oncology, Pharmacotherapy +16

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · The Lancet Oncology · 2012 · 614 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa et al. · The Lancet Oncology · 2016 · 497 citations · Full text

Medicine, Immunology, Oncology +16

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Z. Mark, Petr Zatloukal et al. · Journal of Clinical Oncology · 2011 · 244 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer

Jean-Louis Pujol · Lung Cancer · 2003 · 95 citations

Medicine, Cancer Biology, Oncology +16